Xencor has dosed the first patient in the DUET-2 clinical trial, a Phase l trial of XmAb20717 for the treatment of patients with selected advanced solid tumours.

A total of 87 patients are expected to be enrolled in the first-in-human, open-label, multiple-dose, dose-escalation trial.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial is designed to characterise the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary anti-tumour activity of intravenous administration of XmAb20717 in the enrolled patients.

Xencor chief medical officer Paul Foster said: “Built on the scaffold of Xencor’s XmAb bispecific Fc domain, XmAb20717 is the most advanced candidate in our suite of tumour microenvironment activators.

“Built on the scaffold of Xencor’s XmAb bispecific Fc domain, XmAb20717 is the most advanced candidate in our suite of tumour microenvironment activators.”

“The dual blockade of PD-1 and CTLA-4 with XmAb20717 may promote superior T-cell activation and proliferation compared to anti-PD-1 alone, and we look forward to studying its safety, tolerability and therapeutic activity in clinical trials.”

XmAb20717 is a bispecific antibody capable of simultaneously targeting programmed death-ligand 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) immune checkpoints to treat multiple advanced solid tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Xencor has so far developed 11 candidates using its XmAb technology and are currently examining the candidates under various internal and external clinical development programmes.

In addition, Xencor intends to submit investigational new drug applications for two additional tumour microenvironment activators, including XmAb23104 and XmAb22841 later this year.

XmAb23104 is a PD-1 x ICOS bispecific antibody, while XmAb22841 is a CTLA-4 x LAG-3 dual checkpoint inhibitor.